ClinicalTrials.gg
Not yet recruitingNCT07632469Updated Jun 10, 2026

mGFR vs tGFR in AKI

A Phase 4 interventional study of transdermal GFR in AKI and GFR, sponsored by Bin Du. Not yet recruiting. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Bin Du · Phase 4, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The goal of this study is to learn if the TGFR device (which uses telmapirazin to continuously measure real-time GFR) works to provide accurate and dynamic kidney function assessment in critically ill adults with acute kidney injury (AKI). It will also learn how tGFR compares with the gold standard measured GFR (mGFR) and other commonly used estimate methods. The main questions it aims to answer are:

  • Does tGFR show good agreement with mGFR over the 0-12 hour period in AKI patients?
  • How do tGFR, mGFR, 4-hour creatinine clearance, kinetic GFR (keGFR), and CKD-EPI eGFR compare across different AKI stages?
  • What are the bias and variability of each method over time?

Researchers will compare tGFR to mGFR (iohexol clearance) to see if tGFR is a reliable alternative for bedside, continuous GFR monitoring. They will also compare tGFR against 4-hour creatinine clearance, keGFR, and eGFR to assess consistency across AKI stages.

Participants will:

  • Wear a single-use tGFR sensor patch on the chest for continuous GFR monitoring
  • Receive iohexol injection for mGFR measurement (gold standard)
  • Provide blood and urine samples for 4-hour creatinine clearance and other tests
  • Undergo repeated GFR assessments over the 12-hour study period
02

Conditions studied

  • AKI
  • GFR

Browse trials for

Keywords

  • acute kidney injury
  • intensive care
  • glomerular filtration rate
03

In context

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

This study's planned enrollment of 50 is below the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

Bin Du is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CU stay ≤ 72 hours;
  • meets KDIGO AKI criteria;
  • age 18-85 years;
  • able to complete blood/urine collection and monitoring

Exclusion criteria

Exclusion Criteria:

  • prior history of CKD stage 4 or higher;
  • anuria;
  • recent contrast agent exposure or kidney transplant history;
  • pregnancy or breastfeeding; expected survival \< 24 hours.
05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    intervention group

    Device: transdermal GFR

Interventions

  • Devicetransdermal GFR

    The tGFR detection system comprised 3 distinct components as follows: (i) the fluorescent tracer agent, Lumitrace, (ii) a single small module containing both the light source and photo detector attached to the upper chest area using a biocompatible adhesive, and (iii) a display monitor that digitizes the acquired fluorescent intensity data and contains the algorithms to convert these data to GFR. Background endogenous fluorescence was acquired after attachment of the module to the chest, followed by a 7 ml i.v. bolus dose of Lumitrace. The monitor shows the fluorescence intensity as it is being acquired and then displays the determined tGFR after data acquisition is completed.

06

What researchers measure

Primary outcomes

  1. To validate the agreement of TGFR with mGFR in AKI patients at both the segmented and overall 0-12 hour levels.

    Time frame: 12 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Dorshow RB, Debreczeny MP, Goldstein SL. GFR Measurement Using Transdermal Detection Methodology. J Am Soc Nephrol. 2025 Feb 7;36(8):1592-1602. doi: 10.1681/ASN.0000000639. PubMed 39918882 ↗
  • Dorshow RB, Debreczeny MP, Goldstein SL, Shieh JJ. Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102). Kidney Int. 2024 Oct;106(4):679-687. doi: 10.1016/j.kint.2024.06.012. Epub 2024 Jul 2. PubMed 38964736 ↗
  • Dixon JJ, Lane K, Dalton RN, Turner C, MacPhee IAM, Chis Ster I, Philips BJ. Continuous Infusion of Low-Dose Iohexol Measures Changing Glomerular Filtration Rate in Critically Ill Patients. Crit Care Med. 2018 Mar;46(3):e190-e197. doi: 10.1097/CCM.0000000000002870. PubMed 29194145 ↗
  • Erley CM, Bader BD, Berger ED, Vochazer A, Jorzik JJ, Dietz K, Risler T. Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients. Crit Care Med. 2001 Aug;29(8):1544-50. doi: 10.1097/00003246-200108000-00008. PubMed 11505124 ↗
  • Molitoris BA. Measuring glomerular filtration rate in the intensive care unit: no substitutes please. Crit Care. 2013 Sep 4;17(5):181. doi: 10.1186/cc12876. PubMed 24004539 ↗
  • Inker LA, Titan S. Measurement and Estimation of GFR for Use in Clinical Practice: Core Curriculum 2021. Am J Kidney Dis. 2021 Nov;78(5):736-749. doi: 10.1053/j.ajkd.2021.04.016. Epub 2021 Sep 11. PubMed 34518032 ↗
  • Dorshow RB, Friedemann J, Ross-Jones J, Johnson JR, Vitale L, Riley IR, Debreczeny MP, Harr J, Trelford LP, Goldstein SL. Accuracy of Point-of-Care Transdermal GFR Methodology. Kidney Int Rep. 2026 Jan 22;11(4):103797. doi: 10.1016/j.ekir.2026.103797. eCollection 2026 Apr. PubMed 41726007 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.

Of 46 non-industry phase 4 interventional studies under Acute Kidney Injury, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 6 months is below that.

Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 8, 2026
StartEst.
Jun 8, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
May 5, 2027
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07632469
Lead sponsor
Bin Du
Responsible party
Bin Du (Senior Consultant Physician;Professor, Peking Union Medical College Hospital) — Sponsor-investigator
First posted
Jun 8, 2026
Start date
Jun 8, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
May 5, 2027 (estimated)
Last update
Jun 10, 2026

Study contacts

Bin Du
Contact
dubin98@gmail.com
86+69155643

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion